Pfizer, Eli Lilly, Janssen and Regeneron are advancing a promising class of analgesic drugs, hoping to
put concerns around autonomic dysfunction and joint destruction behind them.
Read the article published on Nature Reviews Drug Discovery 14, 297–298
Anti-NGF_Pain_Programmes_NatureRevDrugDiscov_2015-1 (1) ( PDF)
See also the post: FDA lifts clinical hold on Pfizer/Lilly’s tanezumab
Leave a reply